Stockscreener 앱 받기
6.09
14.04%
0.75
시간 외 거래:
6.52
0.43
+7.06%
전일 마감가:
$5.34
열려 있는:
$5.75
하루 거래량:
379.95K
Relative Volume:
2.80
시가총액:
$13.53M
수익:
$895.50K
순이익/손실:
$-26.30M
주가수익비율:
-3.7134
EPS:
-1.64
순현금흐름:
$-23.84M
1주 성능:
+36.85%
1개월 성능:
+40.97%
6개월 성능:
-67.37%
1년 성능:
-84.30%
1일 변동 폭
$5.69
$6.8016
1주일 범위
$4.26
$6.8016
52주 변동 폭
$3.65
$48.80
Mainz Biomed N V Stock (MYNZ) Company Profile
MYNZ을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
MYNZ
Mainz Biomed N V
|
6.09 | 13.53M | 895.50K | -26.30M | -23.84M | -1.64 |
|
TMO
Thermo Fisher Scientific Inc
|
597.75 | 228.64B | 42.88B | 6.34B | 7.27B | 16.53 |
|
DHR
Danaher Corp
|
222.74 | 160.17B | 23.88B | 3.90B | 5.30B | 5.28 |
|
A
Agilent Technologies Inc
|
151.52 | 43.27B | 6.51B | 1.29B | 1.37B | 4.42 |
|
IQV
Iqvia Holdings Inc
|
201.36 | 36.55B | 15.32B | 1.41B | 1.96B | 7.62 |
|
IDXX
Idexx Laboratories Inc
|
422.05 | 34.56B | 3.84B | 866.24M | 792.60M | 10.37 |
Mainz Biomed N V Stock (MYNZ) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2024-11-25 | 다운그레이드 | H.C. Wainwright | Buy → Neutral |
| 2023-11-21 | 다운그레이드 | Cantor Fitzgerald | Overweight → Neutral |
| 2022-06-21 | 개시 | H.C. Wainwright | Buy |
Mainz Biomed N V 주식(MYNZ)의 최신 뉴스
Mainz Biomed regains Nasdaq compliance with equity rule By Investing.com - Investing.com Nigeria
Mainz Biomed regains Nasdaq compliance with equity rule - MSN
Mainz Biomed Regains Nasdaq Listing Compliance - TipRanks
Mainz Biomed N.V. Regains Compliance with Nasdaq Capital Market Listing Requirements - GlobeNewswire
Mainz Biomed Achieves Full Nasdaq Compliance, Secures Market Position - StockTitan
Mainz Biomed (MYNZ) Stock Price, News & Analysis - MarketBeat
Mainz Biomed (NASDAQ:MYNZ) Shares Down 3.7% – What’s Next? - Defense World
Mainz Biomed Initiates U.S. Clinical Study to Evaluate - GlobeNewswire
Mainz Biomed Initiates U.S. Clinical Study to Evaluate Performance of Next Generation Test on - The Bakersfield Californian
Mainz Biomed Initiates U.S. Clinical Study to Evaluate Performance of Next Generation Test on Advanced Adenomas over Large Patient Population - Marketscreener.com
Mainz Biomed B.V. Addresses Nasdaq Listing Compliance Issue - TipRanks
Mainz Biomed (NASDAQ:MYNZ) Stock Price Down 5.3% – Here’s Why - Defense World
MYNZMainz Biomed N.V. Ordinary Shares Latest Stock News & Market Updates - StockTitan
Mainz Biomed N.V. Forms Agreement with Quest Diagnostics to Provide Clinical Trials Laboratory Services for Colorectal Cancer Screening Test - Marketscreener.com
Mainz Biomed Partners with Quest Diagnostics to Advance Colorectal Cancer Screening in the U.S. - Citybuzz
Quest Diagnostics (NYSE: DGX) And Mainz Biomed (NASDAQ: MYNZ) Team Up To Commercialize ColoAlert Early Cancer Detection Screening In The U.S. - Nasdaq
Mainz Biomed (MYNZ) Stock Soars In Pre-Hour Session On A New Partnership - Stocks Telegraph
Mainz Biomed stock higher on Quest deal (MYNZ:NASDAQ) - Seeking Alpha
Mainz Biomed partners with Quest for colorectal cancer test - Investing.com
Mainz Biomed Forms Agreement with Quest Diagnostics to - GlobeNewswire
Mainz Biomed Partners with Quest Diagnostics for Major Colorectal Cancer Screening Study - StockTitan
Mainz Biomed stock hits 52-week low at $4.3 amid sharp annual decline - Investing.com
Mainz Biomed stock hits 52-week low at $4.3 amid sharp annual decline By Investing.com - Investing.com South Africa
Mainz Biomed Secures $8 Million in Follow-On Offering - TipRanks
Mainz Biomed Announces Closing of $8.0 Million Follow-On Offering - GlobeNewswire
Mainz Biomed Secures $8M Through Strategic Follow-on Offering with Dual-Warrant Structure - StockTitan
Mainz Biomed prices $8M offering of shares and warrants - MSN
Mainz Biomed Prices $8 Million Follow-On Offering to Boost Diagnostics Operations - TipRanks
Mainz Biomed Announces Pricing of $8.0 Million Follow-On Offering Priced at-the-Market Under Nasdaq Rules - The Manila Times
Mainz Biomed Announces $8M Follow-On Offering with Dual Warrant Structure - StockTitan
Mainz Biomed Partners With Thermo Fisher To Advance Colorectal Cancer Screening - Contract Pharma
Mainz Biomed Announces Reverse Stock Split Soon After Collaborating With MedTech Giant Thermo Fisher Scientific - Benzinga
Mainz Biomed stock hits 52-week low at $0.18 amid market challenges - Investing.com India
Mainz Biomed announces 1-for-40 reverse stock split - Medical Buyer
Mainz Biomed (NASDAQ:MYNZ) Shares Set to Reverse Split on Tuesday, December 3rd - Defense World
Mainz Biomed Announces Stock Split - GlobeNewswire
Mainz Biomed Announces 1-for-40 Reverse Split Amid Nasdaq Compliance Issues | MYNZ Stock News - StockTitan
Q3 EPS Estimates for Mainz Biomed Increased by HC Wainwright - Defense World
Mainz Biomed (NASDAQ:MYNZ) Rating Lowered to “Neutral” at HC Wainwright - Defense World
What You Didn’t Know About Mainz Biomed N.V (NASDAQ: MYNZ) This Week - Stocks Register
Mainz Biomed Inks Major Deal To Develop A Next-Generation Cancer Test - Nasdaq
Mainz Biomed and Thermo Fisher Scientific sign a collaboration agreement - Wiley
Mainz Biomed Considers Reverse Stock Split for Nasdaq Compliance - TipRanks
MAINZ BIOMED NV- The GF Score's 5 Key Aspects of Analysis - GuruFocus.com
Thermo Fisher Scientific and Mainz Biomed Partner to Advance Colorectal Cancer Screening Technology - Citybuzz
Healthcare Giant Thermo Fisher Scientific Inc. (NYSE: TMO) Inks Deal With Mainz Biomed (NASDAQ: MYNZ) To Develop And Commercialize Next Gen Colorectal Cancer Screening - Nasdaq
Mainz Biomed N.V. and Thermo Fisher Scientific Inc. Sign a Collaboration Agreement for the Development of Next Generation Colorectal Cancer Screening Product for Global Markets - Marketscreener.com
Mainz Biomed and Thermo Fisher Scientific Sign a - GlobeNewswire
Mainz Biomed Partners with Thermo Fisher for Next-Gen Cancer Screening Breakthrough | MYNZ Stock News - StockTitan
Mainz Biomed Partners with Thermo Fisher to Advance Colorectal Cancer Screening - Contract Pharma
Is Now The Time To Buy Mainz Biomed N.V. (NASDAQ: MYNZ) Stock? - Stocks Register
Mainz Biomed N V (MYNZ) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.69%
0.37%
자본화:
|
볼륨(24시간):